Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02672 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Mengjing Ji und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4, Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
This study developed a novel PET radiotracer to screen breast cancer patients sensitive to CDK4/6 inhibitors, guiding personalized treatment. Two CDK4/6-targeting precursors were synthesized and evaluated in vitro and in vivo. Three breast cancer cell lines─MCF-7, MDA-MB-231, and MDA-MB-468─were selected based on decreasing sensitivity to palbociclib. Compared to [68Ga]Ga-DOTA-Hexa-CDKi, [68Ga]Ga-DOTA-Bua-CDKi clearly identified cell lines with high sensitivity to palbociclib. PET/CT imaging showed significantly higher uptake of [68Ga]Ga-DOTA-Bua-CDKi (8.40 ± 0.85%ID/g) in MCF-7 tumors 60 min after tracer injection, with significant differences in tumor uptake among the three models (P < 0.05). Blocking assays demonstrated specific tumor uptake of [68Ga]Ga-DOTA-Bua-CDKi. Biosafety tests validated its safety as a diagnostic agent. [68Ga]Ga-DOTA-Bua-CDKi showed highly specific targeting of CDK4/6 and effective contrast imaging in tumor models. To our knowledge, [68Ga]Ga-DOTA-Bua-CDKi is one of the first radiotracers to assess CDK inhibitor sensitivity, offering promise for evaluating patient responses to CDK4/6 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
- Center for Biomedical Imaging, Fudan University, Shanghai 200032, China.
- Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai 200032, China.
ORCID-Profile: Shaoli Song, Zhongyi Yang
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Ji, M., Wang, X., Liu, C., Ma, G., Lu, X., Zhu, B., He, S., Zhang, J., Xu, X., Song, S., & Yang, Z. (2025). Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02672
Vancouver
Ji M, Wang X, Liu C, Ma G, Lu X, Zhu B, et al. Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02672
BibTeX
@article{Ji2025,
author = {Ji, Mengjing and Wang, Xiangwei and Liu, Cheng and Ma, Guang and Lu, Xin and Zhu, Bin and He, Simin and Zhang, Jianping and Xu, Xiaoping and Song, Shaoli and Yang, Zhongyi},
title = {Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02672}
}
EUVIMED